Actively Recruiting
CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer
Led by RenJi Hospital · Updated on 2023-05-16
172
Participants Needed
1
Research Sites
295 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an ambispective, single-center study to evaluate the survival outcomes, adverse events and predictive biomarkers for CDK4/6 inhibitors in patients with hormone receptor-positive advanced breast cancer.
CONDITIONS
Official Title
CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 and older
- Confirmed diagnosis of hormone receptor-positive breast cancer
- Locoregionally recurrent or metastatic disease not suitable for curative therapy
- Have received or plan to receive CDK4/6 inhibitors for advanced disease
- ECOG performance status 0 to 2
- Adequate organ function
You will not qualify if you...
- Unable to swallow pills
- History of immunodeficiency disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China, 200127
Actively Recruiting
Research Team
Z
Ziping Wu, MD
CONTACT
Q
Qi Lu
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here